PortfoliosLab logo
Tools
Performance Analysis
Risk Analysis
Optimization
Factor Model
See All Tools
Portfolio Analysis
Portfolios
Lazy PortfoliosUser Portfolios
Discussions
AIM ImmunoTech Inc. (AIM)
Performance
Risk-Adjusted Performance
Dividends
Drawdowns
Volatility
Financials

Company Info

ISINUS00901B1052
CUSIP00901B105
SectorHealthcare
IndustryBiotechnology

Highlights

Market Cap$21.67M
EPS-$0.43
PEG Ratio0.90
Revenue (TTM)$193.00K
Gross Profit (TTM)-$715.00K
EBITDA (TTM)-$23.12M
Year Range$0.32 - $0.75
Target Price$3.83
Short %0.88%
Short Ratio2.72

Share Price Chart


Loading data...

Compare to other instruments

Search for stocks, ETFs, and funds to compare with AIM

AIM ImmunoTech Inc.

Performance

Performance Chart

The chart shows the growth of an initial investment of $10,000 in AIM ImmunoTech Inc., comparing it to the performance of the S&P 500 index or another benchmark. All prices have been adjusted for splits and dividends.


0.00%200.00%400.00%600.00%800.00%OctoberNovemberDecember2024FebruaryMarch
-99.96%
713.13%
AIM (AIM ImmunoTech Inc.)
Benchmark (^GSPC)

S&P 500

Returns By Period

AIM ImmunoTech Inc. had a return of 7.05% year-to-date (YTD) and 9.53% in the last 12 months. Over the past 10 years, AIM ImmunoTech Inc. had an annualized return of -45.75%, while the S&P 500 had an annualized return of 10.89%, indicating that AIM ImmunoTech Inc. did not perform as well as the benchmark.


PeriodReturnBenchmark
Year-To-Date7.05%10.16%
1 month14.85%3.47%
6 months7.05%22.20%
1 year9.53%30.45%
5 years (annualized)-41.83%13.16%
10 years (annualized)-45.75%10.89%

Monthly Returns Heatmap


JanFebMarAprMayJunJulAugSepOctNovDec
2024-5.68%-3.61%
2023-0.00%-25.81%0.00%2.17%-6.38%

Risk-Adjusted Performance

Risk-Adjusted Performance Indicators

This table presents risk-adjusted performance metrics for AIM ImmunoTech Inc. (AIM) and compares them with a selected benchmark (^GSPC). These performance indicators assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.


Sharpe ratioSortino ratioOmega ratioCalmar ratioUlcer Index
AIM
AIM ImmunoTech Inc.
0.22
^GSPC
S&P 500
2.79

Sharpe Ratio

The current AIM ImmunoTech Inc. Sharpe ratio is 0.22. A Sharpe ratio between 0 and 1.0 is considered sub-optimal.


Rolling 12-month Sharpe Ratio-1.000.001.002.003.00OctoberNovemberDecember2024FebruaryMarch
0.22
2.79
AIM (AIM ImmunoTech Inc.)
Benchmark (^GSPC)

Dividends

Dividend History


AIM ImmunoTech Inc. doesn't pay dividends

Drawdowns

Drawdowns Chart

The Drawdowns chart displays portfolio losses from any high point along the way.


-100.00%-80.00%-60.00%-40.00%-20.00%0.00%OctoberNovemberDecember2024FebruaryMarch
-100.00%
0
AIM (AIM ImmunoTech Inc.)
Benchmark (^GSPC)

Worst Drawdowns

The table below displays the maximum drawdowns of the AIM ImmunoTech Inc.. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.

The maximum drawdown for the AIM ImmunoTech Inc. was 100.00%, occurring on Dec 29, 2022. The portfolio has not yet recovered.

The current AIM ImmunoTech Inc. drawdown is 100.00%.


Depth

Start

To Bottom

Bottom

To Recover

End

Total

-100%Mar 10, 20005739Dec 29, 2022
-61%Sep 10, 1998110Feb 17, 1999258Feb 24, 2000368
-58%Oct 14, 199674Jan 28, 1997167Sep 25, 1997241
-48.84%Nov 21, 199794Apr 8, 199865Jul 13, 1998159
-40.91%Jul 16, 199619Aug 9, 19965Aug 16, 199624

Volatility

Volatility Chart

The current AIM ImmunoTech Inc. volatility is 25.15%, representing the average percentage change in the investments's value, either up or down over the past month. The chart below shows the rolling one-month volatility.


0.00%5.00%10.00%15.00%20.00%25.00%OctoberNovemberDecember2024FebruaryMarch
25.15%
2.80%
AIM (AIM ImmunoTech Inc.)
Benchmark (^GSPC)

Financials

Financial Performance

The chart below illustrates the trends in the financial health of AIM ImmunoTech Inc. over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.

Annual
Quarterly

0.0

Income Statement


Income Statement
Balance Sheet
Cash Flow
Annual
Quarterly

TTM
Revenue

Total Revenue

0.00

Cost Of Revenue

0.00

Gross Profit

0.00
Operating Expenses

Selling, General & Admin Expenses

0.00

R&D Expenses

0.00

Total Operating Expenses

0.00
Income

Income Before Tax

0.00

Operating Income

0.00

EBIT

0.00

Earnings From Continuing Operations

0.00

Net Income

0.00

Income Tax Expense

0.00

Interest Expense

0.00

Other Non-Operating Income (Expenses)

0.00

Extraordinary Items

0.00

Discontinued Operations

0.00

Effect Of Accounting Charges

0.00

Non Recurring

0.00

Minority Interest

0.00

Other Items

0.00
Values in undefined except per share items